Elicio Therapeutics Announces Activation of the Investigator-Initiated Phase 1 Study of Neoadjuvant ELI-002 7P for Pancreatic Ductal Adenocarcinoma

* Phase 1 study conducted by Memorial Sloan Kettering (“MSK”) Cancer Center and funded by The Lustgarten Foundation * Study to evaluate ELI-002 7P in combination with chemotherapy and checkpoint inhibition in the neoadjuvant setting * Expected to enroll 20 patients with resectable or borderline resectable pancreatic ductal adenocarcinoma (“PDAC”) BOSTON, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced the opening of the investigator-initiated (“IIT”) Phase 1 neoadjuvant study (NCT07671339) evaluating ELI-002 7P in combination with chemotherapy and an anti-PD1 checkpoint inhibitor in borderline resectable and resectable PDAC. The multi-center IIT is being conducted by MSK Cancer Center and is being funded by a strategic partnership between The Lustgarten Foundation and Break Through Cancer.